An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms EV-302; KEYNOTE-A39
- Sponsors Astellas Pharma Global Development; Seagen
Most Recent Events
- 13 Jun 2025 Planned End Date changed from 30 Nov 2027 to 1 Mar 2028.
- 19 May 2025 According to a Astellas Pharma media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3).
- 23 Apr 2025 According to an pfizer media release, new exploratory analyses will be presented 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago.